• Guardant Health's Tests Are Pioneering a Shift in Precision Oncology

  • Oct 17 2024
  • Length: 43 mins
  • Podcast

Guardant Health's Tests Are Pioneering a Shift in Precision Oncology

Listen for free

View show details

  • Summary

  • “Our liquid biopsy test alone, we estimate one in four cancer patients in the US are getting it,” Helmy Eltoukhy, cofounder and co-CEO of Guardant Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Eltoukhy joins BI analyst Jonathan Palmer to discuss the underpinnings of the liquid biopsy revolution and how Guardant has stuck to its technology road map since its founding in 2012, launching products in each of the three major market categories. The conversations also covers the company’s recent approval of its Shield colorectal screening test as well as many of the scientific and commercial challenges to standing up the business.

    See omnystudio.com/listener for privacy information.
    Show More Show Less
Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Guardant Health's Tests Are Pioneering a Shift in Precision Oncology

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available